IP Library › Granted Patent US 10,561,638
Granted Patent B2
US 10,561,638 · App. 14/099,882 · Granted Feb 18, 2020

Methods for treating dependence

Inventors: Tom Woiwode (South San Francisco, CA); Mark Moran (South San Francisco, CA); Lesley Pickford (South San Francisco, CA)
Assignee: Biotie Therapies, Inc.
A61K31/4164A61K9/08A61K31/415A61K31/417A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,561,638
App. No.
14/099,882
Granted
Feb 18, 2020
Kind
B2
Abstract

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with Compound A. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.

Claims (11)

1. A method of treating a patient suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance, the method comprising administering to the patient a therapeutically effective amount of nepicastat or a pharmaceutically acceptable salt thereof,

wherein the at least one substance is alcohol, with the proviso that the at least one substance is not both cocaine and alcohol.

2. The method of claim 1 , wherein the method of treatment further comprises co-administering a therapeutically effective amount of at least one other agent selected from the group consisting of a selective serotonin reuptake inhibitor, a serotonin-norepinephrine reuptake inhibitor, a norepinephrine reuptake inhibitor, a norepinephrine-dopamine reuptake inhibitor, a serotonin 5-HT1A antagonist, a dopamine beta-hydroxylase inhibitor, an atypical antidepressant/antipsychotic, a tricyclic, an anticonvulsant, a glutamate antagonist, a gamma-aminobutyric acid (GABA) agonist, a GABA metabolism enzyme inhibitor, a GABA synthesis activator, a partial dopamine D2 agonist, a dopamine metabolism enzyme inhibitor, a catechol-O-methyl-transferase inhibitor, an opioid receptor antagonist, a mood stabilizer, a direct or indirect dopamine agonist, a partial 5HT1 agonist, and a serotonin 5HT2 antagonist.

3. The method of claim 2 , wherein the therapeutically effective amount of least one other agent is selected from the group consisting of benzodiazepine, levodopa, carisprodol, modafenil, gamma-butyrolactone, and gamma-hydroxybutyrate.

4. The method of claim 2 , wherein the at least one other agent is disulfiram.

5. A method of treating at least one phase of substance dependence on at least one substance in a patient, wherein the at least one phase of substance dependence is selected from acquisition, maintenance, extinction, and relapse, comprising administering to the patient a therapeutically effective amount of nepicastat or a pharmaceutically acceptable salt thereof,

wherein the at least one substance is alcohol, with the proviso that the at least one substance is not both cocaine and alcohol.

6. The method of claim 5 , wherein the nepicastat or the pharmaceutically acceptable salt thereof inhibits the development of the acquisition phase in the patient.

7. The method of claim 5 , wherein the nepicastat or the pharmaceutically acceptable salt thereof promotes the development of the extinction phase in the patient.

8. The method of claim 1 , wherein the patient is a woman.

9. The method of claim 5 , wherein the method of treatment further comprises co-administering a therapeutically effective amount of at least one other agent selected from the group consisting of a selective serotonin reuptake inhibitor, a serotonin-norepinephrine reuptake inhibitor, a norepinephrine reuptake inhibitor, a norepinephrine-dopamine reuptake inhibitor, a serotonin 5-HT1A antagonist, a dopamine beta-hydroxylase inhibitor, an atypical antidepressant/antipsychotic, a tricyclic, an anticonvulsant, a glutamate antagonist, a gamma-aminobutyric acid (GABA) agonist, a GABA metabolism enzyme inhibitor, a GABA synthesis activator, a partial dopamine D2 agonist, a dopamine metabolism enzyme inhibitor, a catechol-O-methyl-transferase inhibitor, an opioid receptor antagonist, a mood stabilizer, a direct or indirect dopamine agonist, a partial 5HT1 agonist, and a serotonin 5HT2 antagonist.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2014
From: WOIWODE, TOM; MORAN, MARK; PICKFORD, LESLEY
To: SYNOSIA THERAPEUTICS, INC.
Reel/Frame 032409/0765 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2014
From: SYNOSIA THERAPEUTICS, INC.
To: BIOTIE THERAPIES, INC.
Reel/Frame 032409/0774 →
Continuity (5)
Continuation 12187166 · Aug 6, 2008
Provisional Application 60935323 · Aug 6, 2007
Provisional Application 60956555 · Aug 17, 2007
Provisional Application 60960591 · Oct 4, 2007
Related Publication 20140099336A1 · Apr 10, 2014